DR-0201 is under clinical development by Dren Bio and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for B-Cell Non-Hodgkin Lymphoma have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DR-0201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DR-0201 overview
DR-0201 is under development for the treatment of hematologic neoplasms including relapsed or refractory B-cell non-Hodgkin lymphomas, autoimmune disease, systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), systemic sclerosis (scleroderma), polymyositis, dermatomyositis, primary Sjogren's Syndrome (pSS). It is administered through intravenous route. The drug candidate is a bispecific antibody developed using proprietary targeted myeloid engager and phagocytosis platform technology. It was under development for the treatment for chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse large b cell lymphoma (DLBCL) and high-grade b-cell lymphoma (HGBCL).
Dren Bio overview
Dren Bio is a clinical-stage biopharmaceutical company that specializes in the discovery and development of novel antibody therapeutics. The company’s primary focuses on creating treatments that selectively deplete pathogenic cells and other disease-causing agents. Its main products include its proprietary targeted myeloid engager and phagocytosis platform, and its two first-in-class clinical stage programs, DR-01 and DR-0201. Dren Bio’s products are being evaluated for use in various oncology and autoimmune diseases. Its therapies are designed for patients suffering from conditions such as large granular lymphocytic leukemia (LGLL), cytotoxic lymphoma (CTL), and various autoimmune diseases. The company’s operations and target markets span across various therapeutic areas including oncology, immunology, and neurology. Dren Bio is headquartered in Redwood City, California, the US.
For a complete picture of DR-0201’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
